title: Reduced interferon gamma production by antigen-stimulated cord blood mononuclear cells is a risk factor of allergic disorders--6-year follow-up study.
abstract: BACKGROUND
  It is not sufficient to predict 'high allergic risk newborns' on the basis of increased IgE concentrations of cord blood alone, because a raised cord blood IgE concentration is specific but not sensitive in the prediction of the development of allergic disorders. Warner et al. have reported that interferon gamma (IFN-gamma) production by allergen-triggered cord blood cells is a predictor of atopic eczema, based on the 1-year follow-up study.
  
  
  OBJECTIVE
  We examined whether IFN-gamma production by antigen-stimulated cord blood mononuclear cells (CBMCs) is a risk factor of allergic disorders, based on the 6-year follow-up study.
  
  
  METHODS
  The relationships among cord blood IgE concentrations, IFN-gamma and interleukin-2 (IL-2) productions by antigen-stimulated CBMCs, and the development of allergic disorders in 21 infants for 6 years were investigated.
  
  
  RESULTS
  Atopic dermatitis, atopic dermatitis and allergic rhinitis, or atopic dermatitis and bronchial asthma developed in seven of 21 subjects. The maximal IFN-gamma concentration in culture supernatants of ovalbumin (OA) or bovine serum albumin (BSA) stimulated CBMCs in infants who developed allergic disorders was significantly lower (P < 0.01) than that in infants who did not develop any allergic disorders. In contrast, the maximal IL-2 concentration in culture supernatants of OA- or BSA-stimulated CBMCs in infants who developed allergic disorders was not lower than in infants who did not develop any allergic disorders. Moreover, the IFN-gamma concentrations were negatively correlated with cord blood IgE concentrations.
  
  
  CONCLUSIONS
  Reduced IFN-gamma production by antigen-stimulated CBMCs is a risk factor of allergic disorders.
authors.affiliation: Department of Paediatrics, Gifu University School of Medicine, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Kondo
authors.forename: Y
authors.initials: Y
authors.lastname: Kobayashi
authors.forename: S
authors.initials: S
authors.lastname: Shinoda
authors.forename: R
authors.initials: R
authors.lastname: Takenaka
authors.forename: T
authors.initials: T
authors.lastname: Teramoto
authors.forename: H
authors.initials: H
authors.lastname: Kaneko
authors.forename: T
authors.initials: T
authors.lastname: Fukao
authors.forename: E
authors.initials: E
authors.lastname: Matsui
authors.forename: K
authors.initials: K
authors.lastname: Kasahara
authors.forename: Y
authors.initials: Y
authors.lastname: Yokoyama
mesh_terms: D000941:Antigens / Q000276:immunology / Q000494:pharmacology*; D001249:Asthma / Q000097:blood / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D003876:Dermatitis, Atopic / Q000097:blood / Q000276:immunology; D005312:Fetal Blood / Q000166:cytology*; D005500:Follow-Up Studies; D006801:Humans; D006967:Hypersensitivity / Q000097:blood* / Q000276:immunology; D007073:Immunoglobulin E / Q000097:blood; D007223:Infant; D007231:Infant, Newborn; D007371:Interferon-gamma / Q000096:biosynthesis / Q000187:drug effects*; D007376:Interleukin-2 / Q000096:biosynthesis; D007963:Leukocytes, Mononuclear / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D006255:Rhinitis, Allergic, Seasonal / Q000097:blood / Q000276:immunology; D012307:Risk Factors; D013223:Statistics as Topic; D013997:Time Factors
chemical_list: D000941:Antigens; D007376:Interleukin-2; D007073:Immunoglobulin E; D007371:Interferon-gamma